U.S FDA Approves Mirdametinib (Gomekli, SpringWorks) for Adult and Pediatric Patients With NF1-PN
The Dermatology Digest
FEBRUARY 18, 2025
Treatment advances are crucial to achieving better outcomes for patients and this FDA approval offers hope for NF patients and their families, adds Kim Bischoff, Executive Director, NF Network. It is expected to be available through a specialty pharmacy and specialty distributor network in the United States within two weeks.
Let's personalize your content